Project Grant R01HL168044

Award Date 7/5/24
Completion Date 4/30/29
Dollars Obligated $1.2M
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Iowa City, IA 52242, USA
Similar Awards
This $701,842 Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support research at the University of South Florida to investigate the role of the CDK13 gene in the development of congenital heart defects. The project aims to utilize mouse models and human induced pluripotent stem cell-derived cardiomyocytes to better understand how mutations in CDK13 disrupt RNA processing and lead to cardiac...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $711,039 to the Research Institute at Nationwide Children's Hospital to conduct research on the role of cardiac m6A methyltransferases in the pathogenesis of fetal dilated cardiomyopathy (DCM). The key objectives are to determine the functions of the m6A methyltransferases METTL3 and METTL14 in embryonic mouse myocardium and whether their...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $654,530 to the University of Utah to investigate the role of the serine-threonine kinase SGK1 in regulating cardiac function and metabolism in cardiometabolic heart failure with preserved ejection fraction (cMet HFPEF). The 4-year project aims to determine how cardiac-specific SGK1 signaling, particularly through its phosphorylation of...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The Johns Hopkins University provides $1,402,988.66 in funding from September 1, 2024 to July 31, 2028. The project aims to investigate the role of protein kinase G (PKG) and the ubiquitin ligase CHIP in enhancing the degradation of mutant transthyretin to attenuate cardiac amyloidosis. Key objectives include: Testing if PKG stimulation or expression of a CHIP...
This federal Project Grant award, totaling $2,158,428 and funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research aimed at investigating the role of the glycolytic enzyme pyruvate kinase M2 (PKM2) in mediating hypertension and vascular remodeling. The award supports three specific aims: 1) Studying the involvement of PKM2 activation in vascular smooth muscle cells (VSMCs) in hypertension and vascular...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $618,045 to the University of Arizona to conduct research on identifying new mechanisms and targets for treating diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The primary objectives are to: 1) fully characterize at the atomic level three specific functional domains of the cardiac thin filament linked to the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports research into the regulation of the autophagy pathway and its relationship to cardiomyopathy and heart failure. The $2,185,454 award to Tufts Medical Center Parent, Inc. will fund a 4-year study investigating the mechanistic basis of a genetic variant (FHOD3V1151I) associated with hypertrophic cardiomyopathy. Key objectives...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $694,754 to The Washington University in St. Louis to conduct research on understanding the molecular and cellular mechanisms underlying cardiomyopathies and identifying potential therapeutic interventions. The key objectives are to: 1) determine if patient mutations in the troponin gene can be grouped based on common molecular...
This Project Grant award of $2,351,580.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by The Ohio State University to investigate the KCHIP2-JNK2 axis as a potential therapeutic target for sudden cardiac death (SCD) in heart failure (HF) patients. The key goals of the research are to: 1) Determine how the potassium channel interacting protein KCHIP2 regulates the expression of the JNK2 kinase, and 2) Explore how the...

MEDIATOR KINASE REGULATION OF CARDIAC TRANSCRIPTION - PROJECT SUMMARY/ABSTRACT HYPERTENSION IS A COMMON CHRONIC HEART CONDITION RESULTING IN CARDIAC HYPERTROPHY, DYSFUNCTION AND HEART FAILURE. MEDIATOR KINASE, CDK8 EXPRESSION IS INCREASED IN HUMAN AND MOUSE MODELS OF HEART FAILURE AND IS SUFFICIENT TO INDUCE CHANGES IN GENE EXPRESSION NETWORKS RESULTING IN CARDIAC DYSFUNCTION. THE CURRENT PROPOSAL HAS THREE OBJECTIVES: 1) DETERMINE THE THERAPEUTIC POTENTIAL OF SMALL-MOLECULE CDK8 INHIBITORS. 2) IDENTIFY CDK8 KINASE SUBSTRATES THAT ARE PROMISING, NOVEL THERAPEUTIC TARGETS; AND 3) DETERMINE HOW CDK8 MEDIATES CARDIAC TRANSCRIPTIONAL RESPONSES IN VIVO (E.G., BY PHOSPHORYLATING TRANSCRIPTION FACTORS AND MODIFIERS) USING BOTH THE SMALL-MOLECULE CDK8 INHIBITORS AND CDK8 CONDITIONAL CARDIAC KNOCKOUT MICE. OUR CENTRAL HYPOTHESIS IS THAT CDK8 IN CARDIOMYOCYTES REGULATES THE TRANSITION FROM A STEADY-STATE TO A HYPERTROPHIC GENE PROGRAM, DRIVING FUNCTIONAL REMODELING AND CARDIAC HYPERTROPHY. OUR PRELIMINARY DATA IMPLICATE CDK8 AND ITS SUBSTRATES AS POTENTIAL THERAPEUTIC TARGETS TO REDUCE ACTIVATION OF THE HYPERTROPHIC GENE NETWORK, CARDIAC HYPERTROPHY, AND DYSFUNCTION IN RESPONSE TO PATHOLOGICAL HYPERTROPHIC STIMULI. THE CENTRAL HYPOTHESIS WILL BE TESTED VIA THE FOLLOWING SPECIFIC AIMS: (1) CONFIRM THAT CDK8 CONTROLS THE INITIAL CARDIAC RESPONSE TO PRO- HYPERTROPHIC STRESS [AND IN THE LATER STAGE OF HF DECOMPENSATION]. (2) DETERMINE THE TRANSCRIPTIONAL CONSEQUENCES OF CDK8 EXPRESSION AND ACTIVITY DURING HYPERTROPHIC STRESS. (3) IDENTIFY CDK8 TARGETS THAT DIFFERENTIALLY REGULATE THE CARDIAC HYPERTROPHIC RESPONSE. AT THE SUCCESSFUL COMPLETION OF THE PROPOSED RESEARCH, THE EXPECTED OUTCOMES ARE: AN UNDERSTANDING OF THE CDK8 KINASE-DEPENDENT AND KINASE-INDEPENDENT MECHANISMS THAT SERVE AS A KEY NODAL POINT IN TRANSCRIPTION TO DRIVE CARDIAC PATHOLOGICAL GENE EXPRESSION NETWORKS AND CONTRIBUTE TO HEART DISEASE, AND THE IDENTIFICATION OF POTENTIAL NEW TREATMENT MODALITIES FOR PATHOLOGICAL CARDIAC HYPERTROPHY AND THE SUBSEQUENT DISEASE. THESE RESULTS WILL PROVIDE A STRONG BASIS FOR FURTHER DEVELOPMENT OF THERAPEUTICS TARGETING TRANSCRIPTIONAL MECHANISMS THAT INITIATE REMODELING OF GENE NETWORKS IN RESPONSE TO CARDIAC STRESSORS, WHICH IS EXPECTED TO HAVE A SIGNIFICANT IMPACT ON TREATING HYPERTENSIVE CARDIAC HYPERTROPHY BY POTENTIALLY REDUCING CARDIAC TRANSCRIPTIONAL REMODELING. THIS RESEARCH ALIGNS WITH THE NHLBI'S MISSION TO PROMOTE THE PREVENTION AND TREATMENT OF HEART DISEASE BY FURTHER DEFINING THE ACTIVATION OF THE HYPERTROPHIC GENE NETWORK IN MODELS OF HEART DISEASE.

Posted 7/5/24